Malaria is associated with about a million fatalities annually, largely among young children in zones of intense malarial transmission. The last thing needed would be measures that might increase the severity of clinical malaria. Thus, the finding in a field trial on Pemba Island, Tanzania, that routine oral iron supplementation produced adverse effects in iron-sufficient subjects had a ripple effect throughout the international public health community; it has effectively paralyzed efforts to redress iron-deficiency anemia in malariaendemic regions. From a Hippocratic perspective, we consider the de facto moratorium on oral supplementation in such circumstance as a prudent interim measure. Public health programs to combat iron-deficiency anemia cannot be denied indefinitely to malaria-endemic populations, but the universal campaigns of iron provision cannot simply resume in the manner of the past. Contemporary biological and epidemiological understanding of the coevolution of humans and their pathogens should be able to provide guidance within the context of the essential and harmful aspects of iron. From these evolutionary standpoints, we identify a series of unresolved dilemmas. Toward a way forward, we highlight the pros and cons, as well as possible directions toward short-term strengthening, within three domains: tailored oral iron compounds, iron administration targeted only to irondeficient individuals through screening, and prudent use of antimalarial prophylaxis. Although the tension between the essentiality of iron for humans and its role in pathogen virulence looms through every consideration, this recognition is a starting point toward the weighing of appropriate options balancing benefits and safety.
Introduction
The questions of whether, how, and to what extent iron should be provided in malaria-hyperendemic areas has been much discussed [1] [2] [3] [4] [5] [6] [7] in the aftermath of the Pemba trial [8] . Here, we ask whether and how the protective side of iron deficiency in infections can possibly be reconciled with provision of sufficient iron to avoid the negative consequences of iron deficiency for health and thriving: Which data are missing? What kind of tools need to be developed in an expedited manner? The total malaria burden accounts for some 515 million episodes per year and for some 18% of all childhood deaths in sub-Saharan Africa; this corresponds to 800,000 casualties each year [9, 10] . These figures underpin the urgency of answering the questions asked above.
Toward an evolutionary perspective
Evolution aims at the survival of the fittest. Therefore, we may try to learn from how nature handles iron-related benefits and risks. Under physiological conditions, iron oscillates between the divalent and trivalent valency states. This rare property has been exploited in a number of iron-dependent proteins, such as cytochromes and hemoglobin, to mediate electron transfer and to transport and utilize molecular oxygen safely within biological systems. With the arrival of photosynthesis, atmospheric oxygen tension increased and turned most soil iron to iron hydroxide. This form of "rust" makes iron poorly available to iron-requiring Klaus Schümann and Noel W. Solomons Klaus Schümann is affiliated with the Research Center for Nutrition and Food Science (ZIEL), Technische Universität München, Freising, Germany; Noel W. Solomons is affiliated with the Center for Studies of Sensory Impairment, Aging and Metabolism (CeSSIAM), Guatemala City, Guatemala.
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Can iron supplementation be reconciled with benefits and risks in areas hyperendemic for malaria? organisms. With increasing oxygen tension, on the one hand, iron became a scarce biological resource, while its value in an increasing number of iron-dependent proteins increased. On the other hand, the redox properties of free iron catalyze the generation of reactive oxygen species (ROS), which are capable of oxidizing lipid membranes, proteins, and nuclear DNA and, thus, are a risk for cell survival [11] . Via such oxidative stress and combined with impaired protein folding in the endoplasmic reticulum (ER stress) [12] , iron participates in the pathogenesis of inflammation.
As a consequence, evolution faced the dual challenges of improving iron availability while, at the same time, limiting the concentration of free iron in the body [13] . Homeostatic mechanisms evolved to regulate and handle free iron concentrations safely. Plants developed methods to extract oxidized iron from the soil in spite of its minimal solubility. Vegetarian animals living on plant-based diets absorb nonheme iron via homeostatically regulated pathways that are shared by omnivorous species, including humans. In spite of these adaptations, however, iron remained a scarce resource for animals and humans, as hydroxides and other poorly soluble iron complexes also form under the conditions found in the gut lumen [14] .
Poor iron availability also has a protective side, and the organism comes under certain risks when highly bioavailable oral iron preparations are ingested. Therefore, such preparations must be used prudently. Once absorbed, iron is preferentially channeled to the synthesis of iron-dependent proteins [15] . Iron is cleared from the plasma significantly faster and to a larger extent in iron deficiency [16] . The fact that iron-deficient individuals utilize available iron almost completely for their own purposes, rendering this essential resource scarce for parasites, explains why iron status can decisively influence the impact of iron supplements on the course of disease.
Two classes of mechanisms adapt the host's iron kinetics according to the demand for the nutrient [13] : first, the proteins of cellular iron uptake and storage adapt free intracellular iron content to demand by means of the iron-regulatory element/iron-regulatory protein (IRE/IRP) mechanism [17] ; second, intestinal iron absorption and iron sequestration in the reticuloendothelial system are regulated by hepcidin [18] . The hepcidin-related machinery interacts mutually with the pathogenesis of inflammation. This interaction can lead to the "anemia of inflammation, " as hepcidin concentration increases in inflammation and reduces the amount of iron provided to progenitor cells of the bone marrow for erythropoiesis [19] .
This mechanism is protective insofar as it reduces ROS generation and keeps iron scarce for pathogens. However, it can be overwhelmed by highly bioavailable oral iron preparations. Increased mortality of tuberculosis patients after iron supplementation was described as early as the 1850s [20] . With respect to the major plague of the modern era, HIV/AIDS, elevated iron status has been found to correlate with early mortality in HIV patients [21] . Malaria plasmodia adapt to their changing environment as well. They have even learned to direct the host's defense mechanisms against competing plasmodia populations. The blood-stage malaria merozoites increase hepcidin concentrations, which in turn impairs chances for liver-stage superinfection by a new plasmodia population after a second bite, as shown in the Plasmodium berghei ANKA mouse model [22] . These observations underscore the importance of well-regulated iron homeostasis for the clinical course of infective diseases, including malaria. It also shows the complexity of the battle over iron supplies within the host; it is a permanent struggle, not only between hosts and parasites, but also between different groups of parasitic pathogens [23, 24] .
The dilemma of provision of iron in malaria hyperendemic areas
Regarding malaria, the effect of iron supplements on the course of the disease attracted worldwide attention with the findings in the Pemba trial, published in 2006 [8] . A negative impact of provision of iron on malaria prognosis had been suspected for decades, although the data remained controversial [25] . To resolve the controversy, the World Health Organization (WHO) launched a large intervention trial, enrolling some 30,000 children aged 6 to 35 months on the island of Pemba off the Tanzanian coast, where malaria is hyperendemic. The study was halted at mid-term after 18 months, when evidence for a more severe course of malaria became obvious in those children receiving iron; these children had significantly more frequent hospitalization and higher mortality than control children or those receiving only zinc supplementation. Thus, a well-intended and well-organized low-dose iron supplementation program placed babies at an increased risk rather than fostering thriving and growth. This observation came as a shock to the public health community, which responded with paralysis, canceling many iron supplementation programs worldwide as a consequence. The carryover effect of the Pemba trial affected a large parallel trial in a nonmalarial area in Nepal, although no increments in iron-related risk were detected in that trial [26] .
Since then, some concerned voices have expressed a dim view of the international withdrawal from universal iron supplementation programs, demanding that iron be provided also in the African malaria belt in sufficient quantities to cope with the negative consequences of iron deficiency [27] [28] [29] . An insufficient amount of iron impairs its essential functions, leading to a number of adverse consequences, including impairment of oxygen transport and storage by hemoglobin and myoglobin; compromising adequate provision of cellular ATP by iron-containing proteins, such as cytochromes; and reducing the disposal of potentially toxic xenobiotics. Moreover, adequate DNA synthesis by ribonucleotide reductase is compromised, impairing growth and cellular immune defense [30, 31] as well as mental and motor development in children [32, 33] . The rates of stillbirth and small-for-gestational age deliveries increase [34] . Thus, iron deficiency is, indeed, a severe handicap, which makes the post-Pemba situation a true dilemma.
On the horns of a dilemma
A potential-but at the same time questionable-way forward would be simply to ignore the consequences of the Pemba findings. Basing their doubts on a meta-analysis of the literature that did not reproduce evidence for increased malaria risk after iron supplementation, Ojukwu et al. [27] recommended simply resuming iron supplementation without screening for iron status. The proposal is to balance the elimination of an estimated 12% increase in the attributable risk of death or hospitalization from malaria after iron supplementation against a 49% increase in potentially preventable iron deficiency [28] . These figures exemplify the problem and underpin its dimensions.
Iron deficiency impairs the provision of iron to pathogens and serves as a nonspecific immune defense [23] . As a consequence, provision of iron may aggravate the risk and course of infective diseases. Accordingly, post hoc analysis of a subgroup in the Pemba trial for which formal laboratory measures of hematologic and iron status were available casts some light on underlying mechanisms [8] . Admittedly, the sample size of 1,218 in the iron-deficient subgroup that was tested in the Pemba trial does not offer abundant statistical power. However, no increase in combined adverse outcomes (deaths and hospitalizations) was found in iron-deficient and malaria-exposed children.
Several reasons for this finding have been proposed. Prentice [4] suggests that too little iron may be available for a hazardous expansion of the parasite population in iron-deficient hosts. Although plasmodia seem to live "in a land of plenty" with regard to iron during their erythrocyte stage, it appears that the parasites cannot readily utilize heme iron and depend on the very small pool of labile ionic iron in erythrocytes [35] . Another notion is that the absorption of a bolus of orally administered supplementary iron will increase the plasma concentration of non-transferrin-bound iron (NTBI) [36] , which was reported to activate the intracellular adhesion molecule 1 (ICAM-1) receptor in the vascular endothelium [37, 38] . This may increase the adherence of parasitized erythrocytes in the microvasculature and contribute to the increased prevalence of severe cerebral and hepatic forms of malaria [37, 39] , as observed in the Pemba trial. Furthermore, iron supplementation in iron-deficiency anemia will increase the proportion of reticulocytes among circulating erythrocytes, for which Plasmodium vivax has a preference [40] . In addition, the increased concentration of zinc protoporphyrin (ZPP) in the erythrocytes accompanying iron deficiency inhibits hemozoin formation and impairs detoxification of heme iron. Increased ZPP concentrations may thus create a toxic environment for plasmodia in the erythrocyte [41] . The tradeoff between milder courses of malaria in children with depleted iron stores, on the one hand, and the sequelae of iron deficiency, on the other, reflects the central dilemma of iron supplementation in malaria-endemic areas. This series of considerations from epidemiologic and mechanistic perspectives sets out the parameters of complex and vexing dilemmas. The following sections endeavor to point the way toward solutions that move the prior considerations onto a roadmap for actions for their harmonization and resolution.
Concepts to tackle the dilemma of harm versus benefit in iron deficiency
The discussion surrounding the mechanisms of ironrelated exacerbation of malaria seems to pivot around three central ideas: to administer iron compounds that improve iron status without formation of NTBI or driving other mechanisms that aggravate the course of disease; to target iron exclusively to iron-deficient individuals, hoping for preferential and accelerated channeling of such iron to the "safe havens" of the host's functional compartments; and to administer iron while the recipients are protected by antimalarial treatment.
Iron compounds that improve iron status without formation of NTBI
NTBI has been suspected of stimulating the function of ICAM-1 [37, 38] . This, in turn, seems to facilitate attachment of plasmodia-infected erythrocytes to the endothelium and, thus, may compromise cerebral microcirculation and mediate the transfer of plasmodia to cerebral tissue. In addition, other endothelial receptors, such as ED36, and their modulation by tumor necrosis factor α (TNF-α) and by platelet activation may be involved [37, 39] . The surface of the protozoan contains Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1), which, in combination with an integrin receptor (LF1-1), seems to be responsible for adherence of the pathogen to the endothelial surface. Little information is available on the details of interactions of NTBI with this system; this constitutes a gap in knowledge that needs to be filled.
Recent studies showed that plasma NTBI concentrations increase significantly and roughly in proportion to the iron dose after intake of oral ferrous sulfate [36] . No NTBI was observed after administration of the same dosages when iron was administered as an oral slow-release preparation, e.g., as iron polymaltose or sodium iron ethylenediaminetetraacetate (NaFeEDTA) [42] . Still, these iron compounds have been shown to replete hemoglobin deficits effectively [43] [44] [45] . It seems worthwhile to test whether such slow-release compounds have a less negative impact on the clinical course of malaria than does ferrous sulfate. In addition, the effect on iron-malaria interaction of "ready-to-eat fortification, " i.e., uptake of iron together with food, needs to be checked with different iron compounds in this context.
Targeting provision of iron to iron-deficient individuals
To target iron exclusively to those who need it seems like a simple idea, but to set it in operation involves a number of unsolved issues. First, we are not sure about the pathogenetic mechanisms involved in iron-related increments of malaria virulence. Such increments may be caused by postabsorptive peaks in NTBI or plasma iron concentrations, or they could merely be a consequence of a high iron status, which in itself seems to be directly correlated with the prevalence and severity of malaria flares in young children [46] . This notion is not undisputed, though. Decreased hazard ratios for malaria were observed in very young iron-deficient children receiving 18 mg of iron as ferrous sulfate in a multimicronutrient preparation [47] , which is in direct contradiction to a protective effect of iron deficiency. This issue requires clarification with high priority.
If the clinical course of malaria were aggravated by high iron status, one could try to define a (lower) level of iron repletion at which administration of iron should be stopped. The prediction by Cook and Finch [15] states that iron is preferentially distributed into the functional iron compartment, with an even higher preference in iron deficiency. In the functional compartment, iron should be difficult to access by plasmodia. Thus, one might consider a strategy to "titrate" the repletion of body iron stores to a level of "marginal sufficiency." If iron administration were stopped when the erythron had been repleted and anemia was overcome, it would leave the host in a state of what Cook and Finch [15] defined as "iron-deficient erythropoiesis. " In this situation the concentrations of hemoglobin and iron-dependent tissue enzymes should be adequate, but iron stores should still be depleted, with close to no "free iron" being available. This might resolve the dilemma.
However, the proposed concept builds on techniques that are not fully available yet, and the underlying pathophysiological basis poses some questions, the answers to which may render it infeasible. Exact titration of iron status requires close monitoring, which is expensive and difficult to organize in a public health context if based on conventionally determined variables such as hemoglobin, ZPP, and serum ferritin combined with determinations of C-reactive protein (CRP) and alpha-1 glycoprotein (AGP) as biomarkers of concurrent inflammation. Moreover, such conventional screening and monitoring requires repeated blood sampling, which involves substantial costs and a risk of spreading HIV and hepatitis if single use of cannulas and syringes is not strictly guaranteed. Noninvasive methods would be preferable and would also be much better accepted by children and mothers. Furthermore, these methods provide immediate results and spare the patient a second visit. Noninvasive hemoglobin determination by photometric devices applied on the skin surface seems to be coming within reach (e.g., Haemospect®, MBR, Wuppertal, Germany; Pronto-7 and RAD-87®, Masimo, Irvine, California, USA; NBM 200®, OrSense, Petah-Tikva, Israel), although the precision, reproducibility, and validity of hemoglobin values determined by such methods still need more validation [48, 49] , and, at the moment, only Haemospect® and RAD-87® can be applied in infants and small children.
To differentiate between the anemia of chronic disease and iron-deficiency anemia is another prerequisite, as iron should only be provided to patients with iron-deficiency anemia. In anemia of chronic disease, when the body tries to reduce free iron concentrations, iron supplementation may be fatal, as suggested by the Pemba trial. An algorithm to assess inflammatory states by noninvasive photometry is currently under development (personal communication, MBR Optical Systems, 2012). Moreover, Beckmann Laser, Irvine, California, USA, proposed the development of a noninvasive laser photometer to assess tissue ZPP, if financing were available (personal communication, B. Tromberg, 2010). Use of such noninvasive, field-friendly tools may soon permit the targeting of iron supplements exclusively to iron-deficient subjects at low cost and low risk. The development of such an option needs preferential support [1] . Such noninvasive screening tools would, in theory, allow titration of iron administration, so as not to exceed the marginal state of sufficiency. Controlled by such methods, the accumulation of iron stores could possibly be avoided by stopping iron supplementation when a swing beyond the assumed equipoise point occurs, i.e., when the host's functional compartments are repleted and additional iron would be available to foster the virulence of iron-dependent pathogens.
Antimalarial drugs to treat anemia in malariaendemic areas
There is no doubt that overt malaria requires adequate antimalarial treatment. However, prophylactic use of antimalarials has its downside. The risk of inducing drug resistance in plasmodia on a large scale is of most concern. Malaria plasmodia show antigenetic switches; such mutations occur at a frequency of up to 2% per generation [50] and enable the parasites to respond rapidly to selective pressure. Thus, P. falciparum quickly developed resistance against chloroquine and sulfadoxine/pyrimethamine [51] , which was apparently related to its large-scale prophylactic use among tourists in the 1970s and 1980s [52] . Accordingly, the efficacy of artemisinin, the presently valid first-line treatment for P. falciparum malaria, is rapidly declining due to its wide use [53] . Another downside is that prophylactic use of antimalarial drugs will expose the healthy fraction of the population to a number of side effects [54] without any corresponding benefit. This violates the general treatment rules for proper use of antimicrobial agents [55] . Moreover, some antimalarials, such as sulfadoxine/pyrimethamine, interact with iron when taken together [56] . Thus, the prophylactic use of antimalarials to shield entire populations against more severe courses of malaria during general iron supplementation carries the risk of very rapidly blunting the effect of the most effective cutting-edge antimalarial drugs, although the advantages of such treatment for anemia control in malaria-endemic areas have been clearly demonstrated [57] .
Alternatively, it has been proposed to shield only high-risk groups from malaria prophylactically with antimalarial drugs in order to reduce the risk of iron administration. For example, pregnant women are a main target group for iron supplementation, and prophylactic antimalarial treatment would be limited to the duration of the pregnancy. In areas with seasonal malaria, iron could be administered in the malariafree dry seasons. This, however, makes sense only if the malignant interaction between iron and malaria is related to postabsorptive peaks in plasma iron or NTBI concentrations and not to iron status. Another prophylaxis against malaria is to try to keep Anopheles mosquitoes at bay by use of insecticide-treated bednets and indoor spraying. The downside of such prophylaxis is rapid development of pyrethroid-resistant mosquitoes [58] . Moreover, the frequency of nonsymptomatic malaria in different age groups seems to be a consequence of how rapidly immunity can be acquired; this influences the success of intermittent preventive treatment [59] . Infants are the least exposed segment of the population. They have the highest prevalence of overt malaria [60] , which may make treatment decisions easier for this population segment.
Mixed iron-deficiency and inflammatory anemias
The dilemma of adverse interactions between provision of iron and malaria infection comes to a point when anemia has components of both iron deficiency and inflammation in parallel. Unfortunately, asymptomatic malaria with a clear inflammatory component combined with endemic iron deficiency seems to be frequent in the malaria/iron-deficiency belt [60, 61] . The inflammatory component is difficult to verify without testing for blood-stage plasmodia: in 48 % of asymptomatic malaria cases, CRP was not elevated [61] . Antimalarial treatment of such patients abolished parasitemia and normalized iron absorption [61, 62] . In this study, the regulation of body iron distribution was much less affected by antimalarial treatment than was iron absorption, corresponding to the higher sensitivity of hepcidin-mediated impairment of the divalent metal transporter-1 (DMT-1) and the iron uptake step and less, as previously thought, of the ferroportin-mediated intestinal iron export step [18] .
In an ideal world, malaria would be treated before iron was supplied. This would reduce hepcidin concentration and normalize iron absorption and regulated iron distribution. Moreover, in such a world, iron would only be given in cases of iron deficiency. Such an ideal world, however, would require targeting, i.e., assessment of inflammatory and iron status before initiating corresponding treatment, which is exactly what evolution has done. This brings us back to the questions raised above: Can we define the contributions of iron deficiency and inflammation, preferably by noninvasive methods? If not, how can we provide iron at lowest risk? How can we make intelligent use of prophylactic antimalarial shielding at the lowest risk?
With regard to targeting, urinary hepcidin is a promising noninvasive tool. It reflects plasma hepcidin sufficiently well [63] , even in malaria [56, 61] . For this purpose, the reliability of ELISA assays for hepcidin in urine needs to be validated under field conditions, and economy of scale needs to bring the costs of such assays down to affordable levels. In parallel, the use of reflex photometry for noninvasive assessment of microvascular responses to inflammation and laser-based noninvasive ZPP determination should be developed and tested for its applicability in malaria (e.g., Haemospect and Beckmann Laser). However, these tools cannot determine whether inflammation and iron deficiency are caused by malaria or by other kinds of inflammation, such as autoimmune diseases on the one hand, and blood loss or infections with intestinal parasites, on the other hand; such discrimination is decisive for effective treatment.
Conclusions
Public health programs to combat iron-deficiency anemia cannot be denied indefinitely to malariaendemic populations. Nevertheless, we cannot simply resume provision of iron in the universal campaign manner of the past either. As illustrated in this narrative analysis, the malaria-iron interaction and its associated problems are unfortunately very complex. To be promising, a revised public health approach needs to be adopted to relate iron administration to individual iron demand, which in turn requires an affordable and acceptable monitoring system. These traits mimic those of iron homeostasis that evolved to manage the balancing act between the body's demand for iron and the mandate to keep free iron minimally available to parasites. As iron homeostasis can be overwhelmed by highly bioavailable iron compounds, such compounds have to be applied prudently in the course of iron supplementation programs. To balance the advantages of iron deficiency for "nutritional immunity" with the advantage of iron repletion for the host, a number of gaps in present-day knowledge need to be filled. We need to find out whether the higher prevalence of severe courses of clinical malaria is related to the state of iron repletion or to modulations of peak plasma iron or NTBI concentrations caused by recently absorbed oral iron. In the second instance, we need to ascertain to what extent this can be avoided by use of slowrelease preparations that show much lower postabsorptive peaks in plasma iron and produce no NTBI. For individualized provision of iron, the development of noninvasive screening options for hemoglobin concentrations as well as iron and inflammatory status seems a prerequisite.
